中国临床药理学与治疗学2025，Vol.30Issue(9)：1290-1296,7.DOI:10.12092/j.issn.1009-2501.2025.09.016
全球首个PD-1/VEGF双特异性抗体:依沃西单抗
The world's first PD-1/VEGF bispecific antibody:ivonescimab
摘要
Abstract
Ivonescimab is a humanized bispecific antibody targeting human vascular endothelial growth factor-A(VEGF-A)and programmed death protein-1(PD-1).It was approved by National Medi-cal Products Administration on May 24th,2024,and can be used in combination with pemetrexed and carboplatin for locally advanced or positive EG-FR gene mutation after treatment with epidermal growth factor receptor(EGFR)tyrosine kinase inhib-itor.This paper mainly introduces the research progress of the world's first PD-1/VEGF bispecific antibody ivonescimab,and summarizes the mecha-nism of action,pharmacokinetics,phase Ⅰ-Ⅲ clinical trials and drug safety.关键词
依沃西单抗/非小细胞肺癌/PD-1/VEGF/抗肿瘤药Key words
ivonescimab/non-small cell lung can-cer/PD-1/VEGF/antineoplastic drug分类
医药卫生引用本文复制引用
孙彩红,胡涛桃,肖幸幸,袁梦男,江思民,陈寅琪,阮国栋..全球首个PD-1/VEGF双特异性抗体:依沃西单抗[J].中国临床药理学与治疗学,2025,30(9):1290-1296,7.基金项目
浙江省药学会公立医疗机构药品集采规范化管理专项科研资助项目(2024ZYYJ21) （2024ZYYJ21）
